Aktis Oncology (AKTS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $15.06, -5.93% vs the prior close of $16.01.
- Volume 394.80K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
AKTS slides 5.9% to $15.06, a 6-month low, 5 down days in a row. Closed at $15.06, -5.93% vs the prior close of $16.01. Day range $14.84–$16.37, opened at $16.04.
AKTS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — AKTS slides 5.9% to $15.06, a 6-month low, 5 down days in a row
- Closed at $15.06, -5.93% vs the prior close of $16.01. Day range $14.84–$16.37, opened at $16.04.
- Volume was 394.80K shares, 1.0x its 50-day average of 383.94K.
- Price is -32.2% vs its 50-day average ($22.22).
- 52-week range $14.72–$34.19; today's close sits at 2% of that range, 56.0% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — AKTS dips 2.9% to $16.01, a 6-month low, 4 down days in a row
- Closed at $16.01, -2.91% vs the prior close of $16.49. Day range $15.77–$17.08, opened at $16.65.
- Volume was 667.70K shares, 1.8x its 50-day average of 375.55K.
- Price is -28.5% vs its 50-day average ($22.39).
- 52-week range $14.72–$34.19; today's close sits at 7% of that range, 53.2% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — AKTS dips 0.9% to $16.49, a 6-month low, 3 down days in a row
- Closed at $16.49, -0.90% vs the prior close of $16.64. Day range $16.22–$17.12, opened at $16.50.
- Volume was 621.80K shares, 1.7x its 50-day average of 369.10K.
- Price is -26.8% vs its 50-day average ($22.52).
- 52-week range $14.72–$34.19; today's close sits at 9% of that range, 51.8% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — AKTS slides 4.0% to $16.64, a 6-month low
- Closed at $16.64, -4.04% vs the prior close of $17.34. Day range $16.60–$17.61, opened at $17.26.
- Volume was 327.90K shares, 0.9x its 50-day average of 368.83K.
- Price is -26.5% vs its 50-day average ($22.65).
- 52-week range $14.72–$34.19; today's close sits at 10% of that range, 51.3% below the 52-week high.
Oct 12, 2026 — AKTS slides 4.5% to $17.34, a 3-month low
- Closed at $17.34, -4.46% vs the prior close of $18.15. Day range $17.31–$18.19, opened at $18.12.
- Volume was 274.10K shares, 0.7x its 50-day average of 368.92K.
- Price is -23.8% vs its 50-day average ($22.76).
- 52-week range $14.72–$34.19; today's close sits at 13% of that range, 49.3% below the 52-week high.
Oct 9, 2026 — AKTS rises 2.3% to $18.15
- Closed at $18.15, +2.31% vs the prior close of $17.74. Day range $17.58–$18.21, opened at $17.74.
- Volume was 361.00K shares, 1.0x its 50-day average of 368.32K.
- Price is -20.6% vs its 50-day average ($22.86).
- 52-week range $14.72–$34.19; today's close sits at 18% of that range, 46.9% below the 52-week high.
Oct 8, 2026 — AKTS dips 1.4% to $17.74, a 3-month low
- Closed at $17.74, -1.44% vs the prior close of $18.00. Day range $16.99–$17.96, opened at $17.86.
- Volume was 500.80K shares, 1.4x its 50-day average of 364.60K.
- Price is -22.7% vs its 50-day average ($22.96).
- 52-week range $14.72–$34.19; today's close sits at 16% of that range, 48.1% below the 52-week high.
Oct 7, 2026 — AKTS rises 0.8% to $18.00
- Closed at $18.00, +0.78% vs the prior close of $17.86. Day range $17.70–$18.35, opened at $17.72.
- Volume was 294.10K shares, 0.8x its 50-day average of 364.97K.
- Price is -21.9% vs its 50-day average ($23.05).
- 52-week range $14.72–$34.19; today's close sits at 17% of that range, 47.4% below the 52-week high.
Oct 6, 2026 — AKTS slides 3.6% to $17.86, a 3-month low, 5 down days in a row
- Closed at $17.86, -3.56% vs the prior close of $18.52. Day range $17.81–$18.75, opened at $18.64.
- Volume was 294.80K shares, 0.8x its 50-day average of 364.25K.
- Price is -22.8% vs its 50-day average ($23.15).
- 52-week range $14.72–$34.19; today's close sits at 16% of that range, 47.8% below the 52-week high.
- That makes 5 straight losses.
Oct 5, 2026 — AKTS ends flat (+0.0%) to $18.52, 4 down days in a row
- Closed at $18.52, +0.00% vs the prior close of $18.52. Day range $17.84–$18.68, opened at $18.47.
- Volume was 283.00K shares, 0.8x its 50-day average of 362.46K.
- Price is -20.4% vs its 50-day average ($23.27).
- 52-week range $14.72–$34.19; today's close sits at 20% of that range, 45.8% below the 52-week high.
- That makes 4 straight losses.
Oct 2, 2026 — AKTS ends flat (+0.0%) to $18.52, 3 down days in a row
- Closed at $18.52, +0.00% vs the prior close of $18.52. Day range $17.93–$18.82, opened at $18.75.
- Volume was 338.00K shares, 0.9x its 50-day average of 361.68K.
- Price is -20.8% vs its 50-day average ($23.38).
- 52-week range $14.72–$34.19; today's close sits at 20% of that range, 45.8% below the 52-week high.
- That makes 3 straight losses.
AKTS latest news & SEC filings
Every SEC filing by or about AKTS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Czibere Akos converted options/RSUs into 12,500 shares at $4.95 (≈$61.88K) on Sep 23, 2026; now holds 12,500
- Czibere Akos sold 5,099 shares at $20.19 (≈$102.97K) on Sep 23, 2026; now holds 7,401
- Czibere Akos sold 7,401 shares at $21.03 (≈$155.65K) on Sep 23, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 23, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $3.38M (prior year $1.60M) (+111.4% vs Jun 30, 2025)
- Net income: -$24.14M (prior year -$18.07M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.44 (prior year -$22.39) (loss narrowed vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Herrmann Ken sold 1,350 shares at $24.56 (≈$33.16K) on Jul 20, 2026
- Herrmann Ken sold 3,506 shares at $24.56 (≈$86.11K) on Jul 20, 2026
- Herrmann Ken sold 1,350 shares at $24.56 (≈$33.16K) on Jul 20, 2026
- Herrmann Ken sold 3,506 shares at $24.56 (≈$86.11K) on Jul 20, 2026
- Herrmann Ken sold 1,350 shares at $24.56 (≈$33.16K) on Jul 20, 2026
- Herrmann Ken sold 3,506 shares at $24.56 (≈$86.11K) on Jul 20, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Herrmann Ken sold 3,065 shares at $25.21 (≈$77.27K) on Jul 17, 2026
- Herrmann Ken sold 3,065 shares at $25.21 (≈$77.27K) on Jul 17, 2026
- Herrmann Ken sold 3,065 shares at $25.21 (≈$77.27K) on Jul 17, 2026
- Herrmann Ken sold 3,065 shares at $25.21 (≈$77.27K) on Jul 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 20, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 17, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Things to know before you trade AKTS
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Mar 30, 2026. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.60% (largest 10.8%).
- Liquidity: about 388.37K shares (≈$5.85M) trade per day on average.
- 52-week position: $15.06 vs a range of $14.72–$34.19 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Akos Czibere sold 5,099 shares on Sep 23, 2026.
- Latest filings: 10-Q Aug 13, 2026; 8-K Aug 13, 2026; 10-Q May 11, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
AKTS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 16.04 | 16.37 | 14.84 | 15.06 | 394.80K |
| Oct 15, 2026 | 16.65 | 17.08 | 15.77 | 16.01 | 667.70K |
| Oct 14, 2026 | 16.50 | 17.12 | 16.22 | 16.49 | 621.80K |
| Oct 13, 2026 | 17.26 | 17.61 | 16.60 | 16.64 | 327.90K |
| Oct 12, 2026 | 18.12 | 18.19 | 17.31 | 17.34 | 274.10K |
| Oct 9, 2026 | 17.74 | 18.21 | 17.58 | 18.15 | 361.00K |
| Oct 8, 2026 | 17.86 | 17.96 | 16.99 | 17.74 | 500.80K |
| Oct 7, 2026 | 17.72 | 18.35 | 17.70 | 18.00 | 294.10K |
| Oct 6, 2026 | 18.64 | 18.75 | 17.81 | 17.86 | 294.80K |
| Oct 5, 2026 | 18.47 | 18.68 | 17.84 | 18.52 | 283.00K |
| Oct 2, 2026 | 18.75 | 18.82 | 17.93 | 18.52 | 338.00K |
| Oct 1, 2026 | 19.41 | 20.08 | 18.31 | 18.52 | 305.20K |
| Sep 30, 2026 | 19.83 | 19.87 | 19.23 | 19.47 | 277.30K |
| Sep 29, 2026 | 19.30 | 19.73 | 19.06 | 19.69 | 194.70K |
| Sep 28, 2026 | 19.24 | 19.45 | 19.05 | 19.35 | 223.20K |
| Sep 25, 2026 | 19.71 | 19.81 | 18.97 | 19.43 | 518.90K |
| Sep 24, 2026 | 19.74 | 20.45 | 19.43 | 19.63 | 384.70K |
| Sep 23, 2026 | 21.87 | 21.87 | 19.67 | 19.72 | 589.20K |
| Sep 22, 2026 | 21.69 | 22.22 | 21.45 | 22.11 | 302.00K |
| Sep 21, 2026 | 22.06 | 22.06 | 20.75 | 21.43 | 614.30K |
About Aktis Oncology
Aktis Oncology (AKTS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 2035832.
AKTS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Capital, Llc Ecor1 | Director | Jan 12, 2026 |
| Todd Foley | Director | Jan 14, 2026 |
| Glenn Gormley | Director | Apr 16, 2026 |
| Ken Herrmann | Director | Jul 21, 2026 |
| Helen Susan Kim | Director | Jan 12, 2026 |
| Oleg Nodelman | Director | Jan 12, 2026 |
| Matthew Roden | President and CEO | Jan 8, 2026 |
| Lloyd Mitchell Segal | Director | Jan 12, 2026 |
| Michael A. Sherman | Director | Jan 8, 2026 |
| Mary Thistle | Director | Jan 8, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Akos Czibere | Chief Medical Officer | Sep 24, 2026 |
| Paul L Feldman | Chief Scientific Officer | Jan 8, 2026 |
| Kyle D. Kuvalanka | Chief Financial Officer | Jan 8, 2026 |
| Matthew Roden | President and CEO | Jan 8, 2026 |
| Shulamit Ron-Bigger | Chief Operating Officer | Jul 10, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 23, 2026 | Akos Czibere | Sale | 5,099 | $20.19 |
| Sep 23, 2026 | Akos Czibere | Sale | 7,401 | $21.03 |
| Sep 23, 2026 | Akos Czibere | Sale | 5,099 | $20.19 |
| Sep 23, 2026 | Akos Czibere | Sale | 7,401 | $21.03 |
| Sep 23, 2026 | Akos Czibere | Sale | 5,099 | $20.19 |
| Sep 23, 2026 | Akos Czibere | Sale | 7,401 | $21.03 |
| Sep 23, 2026 | Akos Czibere | Sale | 5,099 | $20.19 |
| Sep 23, 2026 | Akos Czibere | Sale | 7,401 | $21.03 |
| Jul 20, 2026 | Ken Herrmann | Sale | 1,350 | $24.56 |
| Jul 20, 2026 | Ken Herrmann | Sale | 3,506 | $24.56 |
| Jul 20, 2026 | Ken Herrmann | Sale | 1,350 | $24.56 |
| Jul 20, 2026 | Ken Herrmann | Sale | 3,506 | $24.56 |
| Jul 20, 2026 | Ken Herrmann | Sale | 1,350 | $24.56 |
| Jul 20, 2026 | Ken Herrmann | Sale | 3,506 | $24.56 |
| Jul 20, 2026 | Ken Herrmann | Sale | 1,350 | $24.56 |
AKTS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $557.60M, total liabilities $72.76M, cash $82.49M (as of Jun 30, 2026).
AKTS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $23.79 |
| May 11, 2026 | 8-K Item 2.02 (results) | $18.27 |
| Mar 30, 2026 | 8-K Item 2.02 (results) | $16.54 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on AKTS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.